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EDITORIAL COMMENT
Restenosis: Do We Need to
Understand It to Treat It?*
David Faxon, MD, FACC
Chicago, Illinois
“There is, we believe, both in pathogenesis and in therapeutics:
much remedy, little cure; much theory, little truth.”
—Pierre Marie, 1883, Archive de Neurologique
Restenosis has been the major therapeutic challenge of
interventional cardiology over the past two decades. An-
dreas Gru¨entzig reported that restenosis occurred in 30% of
his initial patient population (1). Since then, the number of
patients developing restenosis has increased, largely because
of the treatment of more complex cases. In the early to
mid-1990s, coronary stents were introduced, and they have
made a significant impact on the practice of interventional
cardiology. Their popularity is due not only to the fact that
they reduce restenosis, but also that they are relatively easy
to use, they result in a reliable, superior angiographic result,
and they have helped level the playing field among opera-
tors. Despite improved outcomes, coronary stents also
develop restenosis within or adjacent to the stent. Although
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the risk of in-stent restenosis is 10% to 15% lower than with
balloon angioplasty or other interventional devices, it poses
a more formidable problem because the rate of repeat
restenosis is higher than that seen with balloons or other
devices and the restenosis is often more difficult to treat.
This is particularly true when the restenosis is proliferative
or results in total occlusion of the vessel (2).
The Holy Grail for interventional cardiology has been to
find a cure for restenosis. The list of drugs and devices that
have been used in attempts to prevent restenosis is extensive,
and more than 650 clinical trials have been reported in the
literature over the past 20 years. Clinical trials and registries
have helped to further define the problem of restenosis.
Early studies of balloon angioplasty demonstrated that the
final angiographic result was the most important factor in
predicting restenosis. Although stents are capable of attain-
ing an optimal angiographic result with a minimal residual
stenosis, it was not until the mid-1990s that the mechanism
of the benefit of stenting was clearly demonstrated to be the
prevention of unfavorable remodeling. Vascular remodeling
was demonstrated in animal studies and subsequent intra-
vascular ultrasound studies to be the main contributor to
restenosis, contrary to the prevailing theory that neointimal
hyperplasia was dominant (3,4). In fact, numerous studies
have demonstrated that stents actually result in more neo-
intimal growth than does balloon angioplasty, but because
of the larger final lumen diameter, restenosis at follow-up is
significantly less.
Currently, stents are placed in 70% to 80% of patients.
The factors that lead to subsequent restenosis after stenting
are surprisingly similar to those that contribute to restenosis
after balloon angioplasty. In an analysis of 6,180 patients
pooled from six recent native artery coronary stent studies,
Cutlip et al. (5) in this issue of the Journal have shown that
clinical restenosis defined as target lesion revascularization,
target vessel revascularization, or target vessel failure was
related to the initial lumen diameter, the final lumen
diameter, stent length, diabetes, unstable angina, and hy-
pertension and inversely related to myocardial infarction
and cigarette smoking. These factors, however, have only a
fair discriminatory ability (C statistic of 0.68). In addition,
most of these independent predictors are of limited value in
selecting patients or altering the procedure, because it is
now well accepted that every effort should be made to
achieve a minimal residual stenosis. Another major contri-
bution of the study, however, was the observation that
clinical restenosis, as opposed to angiographic restenosis,
has a more delayed presentation than previously appreci-
ated. In this analysis, the rate of clinical restenosis (TVF)
increased from 9.4% at six months to 16% at one year,
emphasizing the need for more prolonged follow-up in trials
evaluating new devices or drugs.
It is evident that restenosis continues to be a major
clinical problem despite the introduction of stents. Even
though stents have had a significant impact in reducing
stenosis by 10% to 15%, restenosis continues to occur at a
disturbingly high rate (6). However, further reduction has
only recently been shown to be possible, with the use of
intravascular radiation therapy or drug-eluting stents. Intra-
vascular radiation, or brachytherapy, with beta or gamma
sources has been shown to be an effective treatment for
in-stent restenosis in native or saphenous vein grafts and has
reduced the rate of subsequent restenosis by 40% to 60%
(7–10). Radiation, however, has not been clearly shown to
prevent restenosis in de novo lesions after balloon angio-
plasty or stent placement (11).
The most important recent development has been the
preliminary results of drug-eluting stents (12–15). Stents
eluting rapamycin or paclitaxel have been shown to reduce
restenosis to4% at six months in selected patients. Not all
drugs appear to be effective; for instance, agents such as
actinomycin D or QUA DDS-QP2 have failed to show
long-term benefit. Unlike radiation, drug-eluting stents
appear to be effective in the initial procedure, and early
evidence suggests that they may also be effective in prevent-
ing subsequent restenosis after the development of in-stent
restenosis (16). Much larger trials are currently ongoing,
and the results of these studies will clearly be necessary for
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us to fully understand the benefits and risks of these new
devices; but there is little question that they appear to offer
enormous promise.
The proposed mechanism of benefit of both radiation and
drug-eluting stents is the inhibition of proliferation of
smooth muscle cells, without the creation of excessive cell
death, as it is the common belief that in-stent restenosis is
largely due to smooth muscle cell proliferation. Although
the proposed mechanism is supported by experimental
studies, human pathologic data are lacking. The study by
Chung et al. (17) in this issue of the Journal raises questions
about the mechanism of in-stent restenosis. In this study, 29
coronary artery in-stent restenotic tissue samples retrieved
by directional coronary atherectomy were analyzed. The
authors found a low cell-proliferation rate, an increase in
myxoid tissue, and cell-depleted areas in 57% of specimens.
Although the study did not evaluate specimens obtained
early after stenting, these findings suggest that extracellular
matrix formation is a much more important component of
in-stent restenosis than previously thought. These new
findings again emphasize how limited our understanding of
restenosis and in-stent restenosis is. It is not uncommon in
cardiology to have effective treatments before we completely
understand the mechanism of benefit. For instance, the
mechanism of angioplasty was not understood for more
than 10 years after its introduction, and stents were shown
to be effective in reducing restenosis before we understood
the role of remodeling in restenosis. Despite our therapeutic
advances in dealing with restenosis, the challenge for the
future is to obtain better understanding of the mechanisms
involved, because this is the only way to optimize effective
treatment and to prevent restenosis. In addition, this un-
derstanding will help us to understand the vascular response
to injury and atherosclerosis. Even though current therapy
for restenosis with drug-eluting stents may well be an
effective treatment, the Holy Grail should perhaps shift to
finding the means of avoiding the need to place stents in the
first place.
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